Malignant transformation (oral cancer development) · People with a diagnosis of oral leukoplakia
It is very uncertain whether vitamin A or retinoids (systemic or topical; incl. 13-cis-retinoic… changes oral cancer development compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Malignant transformation (oral cancer development) · People with a diagnosis of oral leukoplakia
It is very uncertain whether topical bleomycin changes oral cancer development compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Clinical resolution (oral lesion not completely resolved) · People with a diagnosis of oral leukoplakia
It is very uncertain whether topical bleomycin changes clinical resolution (oral lesion not completely resolved) compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Clinical resolution (oral lesion not completely resolved) · People with a diagnosis of oral leukoplakia
1 finding from 1 review
Clinical resolution (oral lesion not completely resolved) · People with a diagnosis of oral leukoplakia
1 finding from 1 review
SoF 4, Clinical resolution (not completely resolved) at 3 to 6 months: '3 studies (freeze-dried black raspberry gel, green tea extract capsules, mixed tea) did not find evidence of benefit.' No GRADE. Effects text:…
4 studies
GRADE not reported
Malignant transformation (oral cancer development) · People with a diagnosis of oral leukoplakia
It is very uncertain whether systemic beta carotene or carotenoids (incl. lycopene) changes oral cancer development compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Malignant transformation (oral cancer development) · People with a diagnosis of oral leukoplakia
1 finding from 1 review
Clinical resolution (oral lesion not completely resolved) · People with a diagnosis of oral leukoplakia
Bowman-Birk inhibitor showed no clear difference in clinical resolution (oral lesion not completely resolved) compared with placebo or no treatment (low certainty).
1 finding from 1 review
Malignant transformation (oral cancer development) · People with a diagnosis of oral leukoplakia
The review found no eligible studies for this question.
1 finding from 1 review
Clinical resolution (oral lesion not completely resolved) · People with a diagnosis of oral leukoplakia
1 finding from 1 review
SoF 2, Clinical resolution (not completely resolved) at 5 to 12 months: 'The 3 studies could not be combined in meta-analysis. 2 found benefit for systemic beta carotene, and 1 did not.' No GRADE rating. Effects text…
3 studies
GRADE not reported
Episode duration associated with oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
Total number of oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
Colchicine (systemic; 0.5 mg weight-adjusted daily) showed no clear difference in total number of oral ulcers compared with placebo (moderate certainty).
1 finding from 1 review
Pain associated with oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
Episode frequency associated with oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
Davies 1988 (aciclovir vs placebo, 36 patients, cross-over; high risk of reporting bias; concomitant treatments): data were not presented in a usable format; authors reported no statistically significant difference in…
1 study · 36 participants
GRADE not reported
Total number of oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
Interferon-alpha (topical; hydrogel or lozenges) showed no clear difference in total number of oral ulcers compared with placebo; GRADE not reported.
1 finding from 1 review
Duration and pain of oral ulceration · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
Alpsoy 2002 (subcutaneous interferon-alpha 6 x 10^6 IU 3x/week for 3 months vs placebo, 50 patients; high risk of reporting bias): data were not presented in a usable format; authors reported a statistically…
1 study · 50 participants
GRADE not reported
Mean number of oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
Melikoglu 2005 (etanercept 25 mg s.c. twice weekly for 4 weeks vs placebo, 40 male patients; high risk of reporting bias): authors reported a statistically significant difference in mean number of oral ulcers with…
1 study · 40 participants
GRADE not reported
Episode frequency associated with oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
SoF (topical interventions vs placebo), grouped comment spanning all four listed outcomes (verbatim): "5 placebo-controlled trials evaluated topical interventions (sucralfate suspension (2 trials), interferon-alpha (2…
Studies not reported
GRADE not reported
Episode frequency associated with oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
Improvement in oral ulcer score · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
Colchicine (systemic; 0.5 mg three times daily for 6 months) showed no clear difference in improvement in oral ulcer score compared with placebo; GRADE not reported.
1 finding from 1 review